Constipation - Pipeline Review, H2 2019
Constipation - Pipeline Review, H2 2019
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.
Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 7, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation - Pipeline Review, H2 2019, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.
Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 2, 7, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Allergan Plc
Ardelyx Inc
Bausch Health Companies Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
Enterin Inc
Inhibikase Therapeutics Inc
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Mallinckrodt Plc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Renexxion LLC
Sanwa Kagaku Kenkyusho Co Ltd
Synthetic Biologics Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-148009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lactulose 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mizagliflozin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Discontinued Products
Constipation - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
Jun 20, 2019: Ironwood and Allergan’s LINZESS trial meets primary endpoint
May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan
Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored
Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada
Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C
Oct 25, 2018: Synergy Pharmaceuticals provides business update
Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting
Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Constipation - Overview
Constipation - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Constipation - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Constipation - Companies Involved in Therapeutics Development
Allergan Plc
Ardelyx Inc
Bausch Health Companies Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
Enterin Inc
Inhibikase Therapeutics Inc
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Mallinckrodt Plc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Renexxion LLC
Sanwa Kagaku Kenkyusho Co Ltd
Synthetic Biologics Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Constipation - Drug Profiles
5-BIOP - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DA-6886 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IkT-148009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lactulose 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
linaclotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lovastatin MR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mizagliflozin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naronapride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGM-282 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
plecanatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenapanor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YH-12852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZS-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Constipation - Dormant Projects
Constipation - Discontinued Products
Constipation - Product Development Milestones
Featured News & Press Releases
Jul 22, 2019: Ironwood Pharmaceuticals Allergan provides update on its ANDA Lawsuit
Jun 26, 2019: Knight announces filing of New Drug Submission for Ibsrela in Canada
Jun 20, 2019: Ironwood and Allergan’s LINZESS trial meets primary endpoint
May 14, 2019: Salix Pharmaceuticals presents data on TRULANCE at Digestive Disease Week
May 09, 2019: Ironwood Pharmaceuticals to highlight linaclotide data at Digestive Disease Week 2019
Jan 18, 2019: Linzess (linaclotide) approved in China for the treatment of irritable bowel syndrome with constipation
Jan 04, 2019: Ironwood and Allergan settle Linzess patent litigation with Mylan
Jan 03, 2019: Synthetic Biologics announces first two patients enrolled in phase 2b investigator-sponsored
Dec 17, 2018: Cipher Pharmaceuticals announces PLECANATIDE accepted for review by Health Canada
Nov 13, 2018: Ardelyx announces FDA acceptance of the filing of its New Drug Application for Tenapanor for the treatment of patients with IBS-C
Oct 25, 2018: Synergy Pharmaceuticals provides business update
Oct 08, 2018: Synergy pharmaceuticals presents new analyses supporting the use of TRULANCE (Plecanatide) in two patient populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Oct 08, 2018: Ironwood Pharmaceuticals presenting Linaclotide Data at the American College of Gastroenterology 2018 Annual Scientific Meeting
Oct 08, 2018: Ardelyx showcases new data from T3MPO-3 long-term safety trial of Tenapanor for IBS-C in presidential poster at ACG 2018 Annual Meeting
Oct 01, 2018: Synergy Pharmaceuticals to present new analyses of TRULANCE (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Constipation, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Constipation - Pipeline by Allergan Plc, H2 2019
Constipation - Pipeline by Ardelyx Inc, H2 2019
Constipation - Pipeline by Bausch Health Companies Inc, H2 2019
Constipation - Pipeline by Braintree Laboratories Inc, H2 2019
Constipation - Pipeline by Dong-A ST Co Ltd, H2 2019
Constipation - Pipeline by Enterin Inc, H2 2019
Constipation - Pipeline by Inhibikase Therapeutics Inc, H2 2019
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019
Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
Constipation - Pipeline by Mallinckrodt Plc, H2 2019
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2019
Constipation - Pipeline by RaQualia Pharma Inc, H2 2019
Constipation - Pipeline by Renexxion LLC, H2 2019
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
Constipation - Pipeline by Synthetic Biologics Inc, H2 2019
Constipation - Pipeline by Yuhan Corp, H2 2019
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019
Constipation - Dormant Projects, H2 2019
Constipation - Dormant Projects, H2 2019 (Contd..1), H2 2019
Constipation - Discontinued Products, H2 2019
Number of Products under Development for Constipation, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Constipation - Pipeline by Allergan Plc, H2 2019
Constipation - Pipeline by Ardelyx Inc, H2 2019
Constipation - Pipeline by Bausch Health Companies Inc, H2 2019
Constipation - Pipeline by Braintree Laboratories Inc, H2 2019
Constipation - Pipeline by Dong-A ST Co Ltd, H2 2019
Constipation - Pipeline by Enterin Inc, H2 2019
Constipation - Pipeline by Inhibikase Therapeutics Inc, H2 2019
Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H2 2019
Constipation - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
Constipation - Pipeline by Mallinckrodt Plc, H2 2019
Constipation - Pipeline by NGM Biopharmaceuticals Inc, H2 2019
Constipation - Pipeline by RaQualia Pharma Inc, H2 2019
Constipation - Pipeline by Renexxion LLC, H2 2019
Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2019
Constipation - Pipeline by Synthetic Biologics Inc, H2 2019
Constipation - Pipeline by Yuhan Corp, H2 2019
Constipation - Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2019
Constipation - Dormant Projects, H2 2019
Constipation - Dormant Projects, H2 2019 (Contd..1), H2 2019
Constipation - Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development for Constipation, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Allergan Plc
Ardelyx Inc
Bausch Health Companies Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
Enterin Inc
Inhibikase Therapeutics Inc
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Mallinckrodt Plc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Renexxion LLC
Sanwa Kagaku Kenkyusho Co Ltd
Synthetic Biologics Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
Number of Products under Development for Constipation, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
Allergan Plc
Ardelyx Inc
Bausch Health Companies Inc
Braintree Laboratories Inc
Dong-A ST Co Ltd
Enterin Inc
Inhibikase Therapeutics Inc
Ironwood Pharmaceuticals Inc
Kissei Pharmaceutical Co Ltd
Mallinckrodt Plc
NGM Biopharmaceuticals Inc
RaQualia Pharma Inc
Renexxion LLC
Sanwa Kagaku Kenkyusho Co Ltd
Synthetic Biologics Inc
Yuhan Corp
Zensun (Shanghai) Sci & Tech Co Ltd
